Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | F12 | P00748 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7015551 | 0.82 | LGMN (0.53) | LGMNSMN1; SMN2ALDH1A1MAPTLMNA | |
| SCHEMBL17893619 | 0.81 | LGMN (0.44) | LGMNSMN1; SMN2ALDH1A1MAPTLMNA | |
| SCHEMBL23152497 | 0.80 | HTR7 (0.46) | HTR7SMN1; SMN2MAPTLMNAKMT2A | |
| SCHEMBL3724026 | 0.79 | LMNA (0.46) | LGMNALDH1A1MAPTLMNAHTT | |
| SCHEMBL17239748 | 0.78 | LGMN (0.44) | LGMNSMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL2273685 | 0.78 | LGMN (0.44) | LGMNSMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL785187 | 0.77 | CHKA (0.53) | LGMNSMN1; SMN2ALDH1A1MAPTF12 | |
| SCHEMBL1982257 | 0.77 | CHRNB4 (0.54) | LGMNSMN1; SMN2ALDH1A1POLBNPC1 | |
| SCHEMBL24126771 | 0.77 | CHKA (0.52) | HTR7ALDH1A1MAPTLMNAHTT | |
| SCHEMBL4169525 | 0.76 | LGMN (0.54) | LGMNSMN1; SMN2ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200299267-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-24 | — | — | US | disclosed |
| US-10717725-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190112293-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-18 | — | — | US | disclosed |
| US-20180099949-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-12 | — | — | US | disclosed |
| EP-3140296-B1 | PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | BRISTOL MYERS SQUIBB CO (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9873679-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3140296-A1 | PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | Bristol-Myers Squibb Company (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2536710-B1 | PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-07-13 | — | — | EP | disclosed |
| WO-2015171722-A1 | PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20150322044-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-11-12 | — | — | US | disclosed |
| US-8486967-B2 | Heteroaryl substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2536710-A2 | PIPERIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2426135-A1 | UREA DERIVATIVE HAVING PI3K INHIBITORY ACTIVITY | Shionogi&Co., Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
| WO-2011101304-A2 | PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | HOFFMANN-LA ROCHE, INC. | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299267-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | LGMN 4507/4885HTR7 285/4885SMN1; SMN2 4640/4885 |
| US-20190112293-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | LGMN 4507/4885HTR7 285/4885SMN1; SMN2 4640/4885 |
| US-10717725-B2 | Pyrrolidine GPR40 modulators | GPR55, GPR65, GPR4 | LGMN 4507/4885HTR7 285/4885SMN1; SMN2 4640/4885 |
| US-20180099949-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | LGMN 4507/4885HTR7 285/4885SMN1; SMN2 4640/4885 |
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | APP, HPGDS, PSEN1 | LGMN 3536/4885HTR7 155/4885SMN1; SMN2 2270/4885 |
| US-20150322044-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | LGMN 4507/4885HTR7 285/4885SMN1; SMN2 4640/4885 |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | LGMN 2627/4885HTR7 4517/4885SMN1; SMN2 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.